Multiple sclerosis (MS) is a chronic, autoimmune disease that affects the central nervous system, leading to impaired vision, loss of balance or coordination, fatigue, and muscle weakness, among many other symptoms that patients may experience.
The cause of MS is unknown, and a complete cure is not available. However, some therapies may slow down the disease progression.1-3 Approved by the US Food and Drug Administration in 2020, ofatumumab is a self-administered SC, targeted B-cell therapy for patients with relapsing MS.4,5 Novartis is looking for additional ways to differentiate ofatumumab medically.
This is an Ideation Challenge with a guaranteed award for at least one submitted solution.
Affecting approximately 2.5 million people worldwide, the typical onset of MS occurs between 20 and 40 years of age, with a greater prevalence in women than men.2 Patients with MS have difficulty performing tasks associated with everyday activities and self-care, which leads to a lower quality of life.7
There are 4 distinct disease courses: clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS), primary progressive MS (PPMS), and secondary progressive MS (SPMS).8 As the name suggests, RRMS is characterized by relapses interspersed with periods of remission; however, there is disease progression that leads to increasing disability over time.9
Submissions to this Challenge must be received by 11:59 PM (US Eastern Time) on July 15, 2022.